Navigation Links
Luminex Corporation Reports Second Quarter 2012 Results
Date:7/30/2012

ments regarding: the expansion of our installed base; distribution for our instruments; purchases of our consumable products; the development progress and market acceptance of our assay products, including NeoPlex4 and NeoPlex System and products developed and manufactured by Luminex Madison and Luminex Molecular Diagnostics; anticipated FDA clearance of our products, including Gastrointestinal Pathogen Panel, NeoPlex4 and NeoPlex System;status of integration of Luminex Madison; the acquisition of GenturaDx; the addition of Luminex to the S&P Small Cap 600 GICS; Luminex's long-term strategic plan and acquisition strategy; the ability of our investment in current initiatives and new products to deliver high performance solutions, and drive long-term value for our shareholders; and, projected 2012 revenue. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.  It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements.  Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex's products and technology, the Company's dependence on strategic partners for development, commercialization and distribution of products, concentration of the Company's revenue in a limited number of strategic partners, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle and bulk purchases of consumables, Luminex's ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, potential shortages of components, competition, the timing of regulatory approvals, the implementat
'/>"/>

SOURCE Luminex Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Luminex Corporation Second Quarter Earnings Release Scheduled for July 30, 2012
2. Luminex Corporation Announces Agreement to Acquire GenturaDx
3. Luminex Corporation Reports First Quarter 2012 Results
4. Unilife Corporation Announces Financial Results For Fiscal Year 2012 Fourth Quarter
5. Gentris Corporation Announces Collaboration to Study Blood Stability
6. Unilife Corporation to Announce Financial Results for Fiscal 2012 Fourth Quarter and Year End on Monday, July 30, 2012
7. Volcano Corporation Schedules Second Quarter Conference Call, Webcast
8. Celladon Corporation Receives Patent from United States Patent and Trademark Office
9. Gentris Corporation Launches New Pharmacogenomics Services
10. BioElectronics Corporation Announces Initiative for UK and German Markets
11. Statement from Mary Vogt, President of Home Access Health Corporation, manufacturer of the Home Access HIV-1 test system, the only over-the-counter HIV test previously approved by the FDA for at-home use.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... DUBLIN , Dec. 24, 2014  Actavis ... that the Company has received a complete response ... (FDA) for its New Drug Application (NDA) for ... for the treatment of hypertension.   Photo ... we are disappointed in the receipt of a ...
(Date:12/24/2014)... China, Dec. 24, 2014 /PRNewswire/  -- Tianyin Pharmaceutical ... pharmaceutical company that specializes in the patented biopharmaceutical, ... active pharmaceutical ingredients (API) released unaudited preliminary financial ... 2015. Fiscal Year 2015 Ended September ... $9.7 million compared with $14.7 million in 1Q14 ...
(Date:12/24/2014)... 24, 2014 Soligenix, Inc. (OTCQB: SNGX) ... developing products that address unmet medical needs in ... today that on December 24, 2014 it closed ... The Company raised approximately $2.3 million in gross ... the net proceeds from the offering to fund ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... the University of Illinois at Chicago are taking part ... 2,000 autism patients and their families over the next ... Collection, is the first coordinated effort to create a ... child. , "This collection of DNA will allow researchers ...
... since last year mean seniors should shop wisely, experts ... the enrollment period for Medicare,s Part D prescription drug ... are advising seniors to choose a plan carefully because ... plan. , "As we enter the fourth year of ...
... published by The Feinstein Institute for Medical ... and disease pathogenesis at the molecular level ... use that knowledge in the design of ... prognosis, and prevention. Featured in the ...
... software free of charge to customers purchasing its market leading ... ... Fort Collins, CO (PRWEB) November 14, 2008 -- Privacy ... Email Integrity Program for customers purchasing Privacy Networks, market leading ...
... diagnostic measures, British researchers report , , THURSDAY, Nov. 13 ... standard test for measuring the activity of the heart ... problems for people who are examined because of chest ... stable chest pain, suspected angina, the resting EKG was ...
... Nov. 13 The U.S. government,through the U.S. ... five planned shipments of U.S. emergency assistance to ... In coordination with the,UN Children,s Fund (UNICEF), approximately ... 5,400 water containers, 500,rolls of plastic sheeting, and ...
Cached Medicine News:Health News:UIC joins international research effort to study autism 2Health News:Enrollment for Medicare Drug Plans Begins Again 2Health News:Enrollment for Medicare Drug Plans Begins Again 3Health News:Researchers Tackle CLL, Diabetes and Trauma-Hemorrhage, 2Health News:Message Archiving Leader Privacy Networks Announces Free Anti-Spam Software to Businesses and Organizations 2Health News:Message Archiving Leader Privacy Networks Announces Free Anti-Spam Software to Businesses and Organizations 3Health News:EKG Not Strong Predictor of Heart Risk 2Health News:EKG Not Strong Predictor of Heart Risk 3Health News:First U.S. Flight with Humanitarian Goods Arrives in Democratic Republic of Congo 2
REFRESH TEARS® lubricating eye drops does more than just smoothe and relieve dry, irritated eyes. REFRESH TEARS® creates a shield of protection against further irritation with its unique, lon...
... REFRESH ENDURA™ is the ... to benefit all 3 layers ... coating of moisture that lubricates ... your eyes). This helps seal ...
ALPHAGAN® (brimonidine tartrate ophthalmic solution) 0.2% is indicated for lowering IOP in patients with open-angle galucoma or ocular hypertension....
... solution is a prescription eye drop ... to use after your cataract surgery. ... may cause them to become inflamed. ... inflammation include redness and swelling. If ...
Medicine Products: